TXNIP and cancer: Notably, decreased expression of TXNIP indicated poorer survival prognosis in seven out of eight cancers, including breast, bladder, skin, lung, brain, eye and soft tissue cancers (Additional file 2: Fig. S2I–S, all P < 0.05).